Targeting Glia for Therapy: Mediators of Neuroinflammation, Degeneration and Repair

Date/Time: Sunday, October 4, 2020 - 4:30 PM – 6:30 PM
Track: Plenary Session
Log in to Add to My Schedule


Nearly half of the brain is composed of glial cells, including oligodendrocytes, astrocytes, and microglia, and each likely contribute to the etiology and progression of neurological disease. In the past several years there have been an increasing number of high-profile, high-impact stories that implicate each of these cells in various neurological disorders that have no curative treatment. This session will focus on recent work highlighting the role of glial cells as the mediators of degeneration, inflammation and repair. A better understanding of the role of glial cells is likely critical to develop novel effective therapies. 


  • Identify the specific glial cell types—astrocyte, oligodendrocyte lineage cells and microglia that are currently being studies in the context of neuroinflammatory and neurodegenerative disease.

  • Identify basic pathomechanisms addressing the role of glial cells mediate in inflammatory and neurodegenerative disease.

  • Identify glial-specific targets to develop reparative therapies.


Glia-Mediated Mechanisms of Chemotherapy-Related Cognitive Impairment

Kv1.3 Channel Expressing Brain Myeloid Cells are a Unique Pro-inflammatory Subset of Microglia Which Can be Modulated by Kv1.3 Blockers in Alzheimer’s Pathology

Oligodendrocyte Precursor Cell Present Antigen and are Cytotoxic Targets in Inflammatory Demyelination

Single Nuclei Transcriptomic Profiling of Human Astrocytes in Alzheimer’s Disease and Aging

Targeting Microglia-Mediated Synapse Elimination for Therapeutic Intervention in Demyelinating Disease